Formulary. Update. Formulary Additions. Page 1 I S S U E 3 V O LU M E 6 J U N E 2012
|
|
- Kelly Wood
- 5 years ago
- Views:
Transcription
1 I S S U E 3 V O LU M E 6 J U N E 2012 u Additions... 1 u Deletions.. 2 u Medicare... 3 u Clinical Updates u Medications Reviewed At P&T, But Not Added To The A P U B L I C AT I O N O F T H E G E O R G I A P H A R M A C Y A N D T H E R A P E U T I C S ( P & T ) C O M M I T T E E. The Update contains information regarding formulary additions, deletions, exclusions, brief descriptions of products, and current drug related news. It also lists items to be discussed at upcoming P&T meetings. Please refer to the web site healthcare/formularies.html or providers.kp.org for the full KP GA Drug. If you have Lexi-Comp PDA access to the KPGA Online, remember to sync your device for the most current information. Update Additions Atorvastatin 10 mg, 20 mg, and 40 mg tablets are currently available on the National MPD as Tier 2, generic, and was added to the Commercial effective June 20, Atorvastatin became generically available in November Atorvastatin 80 mg tablet was added to the Commercial in April 2012, but all other dosage forms of atorvastatin remained non-formulary due to their increased cost when compared to equipotent formulary statins. Since the 6 month exclusivity of generic atorvastatin has expired, new pricing is available for all atorvastatin strengths that provide comparable pricing to our current formulary statins. Pegasys (pegylated interferon alpha-2a) ProClick 130 mg and 180 mg autoinjector is currently available on the National MPD as Tier 5, specialty, and was added to the Commercial effective June 20, Pegasys (pegylated interferon alpha-2a) is FDA approved for the treatment of chronic hepatitis C, alone or in combination with ribavirin, and for the treatment of chronic hepatitis B. Pegasys ProClick is a self-contained administration device that delivers a set dosage of the medication. Prednisone 5 mg dose pack is currently available on the National MPD as Tier 2, generic, and was added to the Commercial effective June 20, Methylprednisolone and prednisone are systemic glucocorticosteroids used to treat a variety of disorders including those of hematologic, allergic, inflammatory, neoplastic and autoimmune origin. Steroid dose packs are prepackaged with specific instructions providing a convenient tracking mechanism to assist in patient adherence. The cost of methylprednisolone 4 mg dose packs and 4 mg tablets has risen significantly. Prednisone 5 mg dose packs provide an equivalent steroid dosage to patients as the methylprednisolone dose packs at a fraction of the cost. Page 1
2 Additions, Cont. Hydrocodone/acetaminophen mg tablet, mg tablet, and mg/15 ml suspension is currently available on the National MPD as Tier 2, generic, and was added to the Commercial effective June 20, Hydrocodone/aceatminophen products are FDA approved for the relief of moderate-tosevere pain. On January 1, 2014 the FDA will begin limiting the amount of acetaminophen in combination prescription products to 325 mg. The products listed above are being added to the formulary so they maybe utilized in place of hyrdocodone/acetaminophen combination products which contain >325 mg acetaminophen. Criteria Restricted Medications Deletions ALL opioid/acetaminophen combination products containing >325 mg acetaminophen will be removed from the Commercial effective January 1, 2013 (please see the list of affected products in the table below). Food and Drug Administration (FDA) is requesting manufacturers of oral prescription acetaminophen (APAP) combination products limit the maximum amount of APAP in these products to 325 mg per tablet, capsule, or other dosage unit by January 14, FDA believes that limiting the amount of APAP will reduce the risk of severe liver injury from APAP overdosing, an adverse event that can lead to liver failure, liver transplant, and death. To comply with the regulation, manufacturers will need to limit the amount of APAP per dosage unit to 325 mg or with draw the drug product from the market. Currently, multiple opioid/apap products containing >325 mg APAP are available on the Commercial. To comply with the regulations, opioid/ APAP products containing >325 mg APAP will be removed from the Commercial and replace the products with formulations that contain 325 mg APAP. The addition of the lower opioid/apap dosage strength formulations listed on the previous page will take place June 20th, 2012, but the removal of the combination products with >325 mg APAP would be delayed until January 2013 to allow time to change prescribing patterns and to educate providers on the formulary change. Hydrocodone/APAP and Oxycodone/APAP products to be removed from the Commercial January 1, 2013: Hydrocodone/APAP mg Hydrocodone/APAP mg Hydrocodone/APAP mg Hydrocodone/APAP mg Hydrocodone/APAP mg Hydrocodone/APAP mg Hydrocodone/APAP mg Hydrocodone/APAP mg/ml Page 2 Oxycodone/APAP mg caplet Oxycodone/APAP mg capsule Vancomycin (generic Vancocin) 125 mg and 250 mg capsules were removed from the Commercial effective June 20, Vancomycin is a glycopeptide antibiotic indicated for treatment of Staph aureus, methicillin-resistant S. aureus, meningitis, pneumonia and endocarditis by intravenous administration and Clostridium difficileassociated diarrhea (CDAD) by oral administration. Vancomycin is considered second line for treatment of CDAD, but due to a more virulent strain of C. diff potentially more patients may require treatment with oral vancomycin. Both vancomycin capsules and oral solution contain the same active medication and therefore should have the same efficacy. Vancomycin compounded oral solution is prepared from injectable vancomycin. Vancomycin 125 and 250 mg capsules cost $1000-$2000 more per prescription than the compounded solution. Criteria restricted medications require review by Quality Resource Management (QRM) prior to coverage. The prior authorization process and criteria apply to the Commercial formulary, not the Medicare Part D formulary. Providers must call QRM to request authorization consideration at (Option 2). A complete listing of prior authorization medications and their corresponding criteria is available on the intranet under Healthcare Delivery/ Guides & Reference/ Formularies/ Criteria Restricted (QRM) Medications. The following medications will be added to the list of Criteria Restricted Medications (QRM) effective July : Dysport (abobotulinumtoxin A) and Xeomin (incobotulinum toxina) are FDA approved for treatment of cervical dystonia in both toxin-naive and previously treated patients. Cosmetic use of botulinum toxins is excluded from coverage under the medical benefit. Bydureon (exenatide ER) is FDA approved for the Treatment of type 2 diabetes mellitus to improve glycemic control. Firazyr (icatibant) is FDA approved for the Treatment of acute attacks of hereditary angioedema (HAE) Juvisync (janumet/simvastatin) is FDA approved for use in patients for whom treatment with sitagliptin and simvastatin is appropriate. Kalydeco (ivacaftor) is FDA approved for treatment of cystic fibrosis in patients who have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
3 Questions and Concerns? If you have any questions or concerns, please contact any of the following P&T Committee members and designated alternates: P&T Chair: Daniel Lee, MD, FACS Physician Program Director of Pharmacy P&T Committee Members: Seeme Ahmad, MD Behavioral Health Debbi Baker, PharmD, BCPS Clinical Pharmacy Gary Beals, RPh Director of Pharmacy Karen Bolden, RN, BSN Clinical Services Deborah Burzotta, PharmD Pharmacy Operations Alyssa Dayton, MD Obstetrics and Gynecology Carole Gardner, MD Elder Care Patrice Gaspard, MD Pediatrics LaJune Oliver, MD Ambulatory Medicine Donald Hanchett, MD Ambulatory Medicine David Jones, MD Pediatrics Felecia Martin, PharmD Pharmacy/Geriatrics Susan Moon, MD Hospitalist Designated Alternates: Jacqueline Anglade, MD Obstetrics and Gynecology Lesia Jackson, RN Clinical Services Margaret Shugart, MD Behavioral Health Deletions, Cont. Pancreaze (pancrelipase) capsules will be removed from the Commercial effective July 18, Pancrelipase 5,000 and Zenpep (pancrelipase) 10,000, 15,000 and 20,000, delayedrelease, enteric-coated capsules are Kaiser Permanente s preferred contracted pancreatic enzyme products (PEPs) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Pancrelipase (5,000 lipase units) is the preferred product for patients requiring lower doses. The deletion of Pancreaze from the Commercial allows for streamlined utilization to the contracted products. Product Pancreatic Enzyme Comparison Chart USP Units (Lipase/Protease/Amylase) National Medicare Part D Kaiser Permanente has a National Medicare Part D (MPD). Each regional P&T Committee reviews drugs and decides on tier status Regional P&T chairs are voting members of an interregional committee that addresses the relatively few drugs for which regional decisions differ. This committee is called MPD Reconciliation Committee (MPD FoRCe). MPD FoRCe resolves differences in formulary decisions. Regional P&T chairs convey the decision(s) back to their respective regional P&T Committees to finalize the National MPD decision(s). National MPD Tier changes are listed below with their corresponding effective date: Medication Name Tier Effective Date Avonex Pen Kit 30 mcg Tier 5 05/01/2012 Korlym tab 300 mg Tier 5 05/01/2012 Lupron Depot inj 45 mg Tier 3 05/01/2012 Lupron Depot-Ped inj 30 mg Tier 3 05/01/2012 Viread pow 40 mg/gm Tier 4 05/01/2012 Viread tab 150 mg, 200 mg, & 250 mg Tier 4 05/01/2012 Vyvanse cap 20 mg, 30 mg, 40 mg, 50 mg, 60 mg & 70 mg Status COM Tier 3 05/01/2012 Tier 1 = Value Generic Tier 3 = Brand Tier 5 = Specialty Tier 2 = Generic Tier 4 = Non-Preferred Brand Tier 6 = Injectable Part D Vaccine MPD Pancrelipase capsule 5,000 / 17,000 / 27,000 F Tier 2 Zenpep capsule 10,000 / 34,000 / 55,000 15,000 / 51,000 / 82,000 20,000 / 68,000 / 109,000 Creon capsule 6,000 / 19,000 / 30,000 12,000 / 38,000 / 60,000 24,000 / 76,000 / 120,000 Pancreaze capsule 4,200 / 10,000 / 17,500 10,500 / 25,000 / 43,750 16,800 / 40,000 / 70,000 21,000 / 37,000 / 61,000 F Tier 3 NF Tier 3 NF Tier 4 COM = Commercial MPD = National MPD Tier 1 = Value Generic Tier 3 = Brand Tier 5 = Specialty Tier 2 = Generic Tier 4 = Non-Preferred Brand Tier 6 = Injectable Part D Vaccine Page 3
4 National Medicare Part D, Cont. Conditional Part B or D Policy for Boniva and EMLA Effective April 1, 2012, prior authorization will be required for Boniva and EMLA. Prior authorization drugs may be covered by Medicare Part D or Part B depending on how and where they are administered and for what medical condition (dialysis). The affected medications include: Boniva Injection 3 mg/3ml Boniva tab 150 mg (ibandronate sodium tablets) Boniva tab 2.5 mg (ibandronate sodium tablets) EMLA cream (Lidocaine/Prilocaine cream %) EMLA/Tegaderm kit It is important that pharmacy claims for these oral ESRD drugs are processed correctly: HealthTrans will return the appropriate Medicare Part B or Part D cost sharing. Conditional PIMS flags have been added. The billing indications are ESRD ON DIALYSIS or OTHER. Pharmacy staff should enter the correct billing indication for the claim to process accordingly (Do not override the cost share to $0). Members should pay the correct Medicare Part B or Part D cost sharing according to their drug benefit. Clinical Updates Safety Advisory for Merck Vaccines and Diluents. The Information SuperHighway workgroup (part of the Interregional Medication Adherence, Reconciliation, and Safety (IMARS) group) has identified some issue regarding vaccines. Background: Through and evaluation of medication related events, some medication errors related to vaccines have been reported from various KP regions: Patients received flu vaccine which was ineffective due to improper shipment method by vendor. Examination of boxes showed that the temperature strip indicated a drop below the appropriate temperature to stay active. During a Saturday flu clinic, 1/2 doses of Fluzone were being administered to children under the age of three, rather than the thimerosal free injections. Members under 18 years of age received FluLaval, adult influenza vaccine. Staff failed to follow policy/procedures requiring that a morning communication huddle be held. Assessment: The recent vaccine issues identified by the Information SuperHighway workgroup that could result in potential patient harm are the following: Vaccines not being mixed with the appropriate diluents (e.g., using diluents other than the sterile diluent supplied by Merck for their vaccines (such as MMR II, Varivax, and Zostavax) can cause inactivation of these live vaccines and reduce their effectiveness in preventing disease. Act-Hib and Manomumne are packaged in the same box with their diluents and there is the potential for mismatches in quantities. Pentacel packages include two vials, with a vaccine in each vial (HIB component power and the Dtp/IPV liquid). The vials must by mixed just prior to administration. Potential to administer the diluent alone, resulting in the patient not actually receiving a complete vaccination. Rotarix vaccine and storage conditions of the different diluents (refrigerator versus room temperature). Recommendations: Pay close attention when reconstituting vaccines to ensure the correct diluent is being used. Prior to mixing and administering vaccines, review the vaccine package insert to ensure appropriate use. Vaccines should be stored at the appropriate temperatures. Page 4 Additional Clinical Alerts Aliskiren-containing Medications: Drug Safety Comunication - New Warning and Contraindication ucm htm Victrelis (boceprevir) and Ritonavir- Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions ucm htm Revlimid (lenalidomide): Ongoing Safety Review - Increased Risk of Developing New Malignancies ucm htm Hospira Carpuject Pre-filled Cartridges - Drug Alert: Products May Contain More Than the Intended Fill Volume ucm htm Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose ucm htm Teva s Adderall 30 mg Tablets: Counterfeit Product - Contains Wrong Active Ingredients ucm htm
5 Upcoming Decisions An important aspect of the formulary process is the involvement of all practitioners. So that each of you has an opportunity to participate in the process, upcoming P&T agenda items are listed below. Please contact your P&T Committee representative or your clinical service chief by July 15, 2012 if you wish to comment on any of the medications, class review, or other agenda items under consideration. To make formulary addition requests, you must submit a Additions/Deletions Form and Conflict of Interest Form to Drug Information Services or call (404) Reviews (August 2012): status of the following medications will be reviewed: Medication Class Reviews Vitamins MVI Minerals & Electrolytes Hematopoetic Agents Anticoagulants Hemostatic Agents Otic Agents Mouth/Throat/Dental Antiseptics & Disinfectants Diagnostic Products Skeletal Muscle Relaxants Endocrine and Metabolic Agents - Misc. Non-narcotic Analgesics Opioid Analgesics Anti-Inflammatory Analgesics Clinical Updates, Cont. REMINDER - Use the proper age-appropriate formulation when prescribing and/or administering hepatitis B vaccine (Engerix-B). Single-antigen hepatitis B vaccine (Engerix- B), manufactured by GSK, is the preferred brand for hepatitis B immunizations in the Georgia Region (except in situations where a combination vaccine containing hepatitis B antigen is recommended or desired). It is available in two different strengths: 0.5-mL (10 mcg) single-dose vials and prefilled syringes labeled for use in pediatrics & adolescents 1-mL (20 mcg) single-dose vials and prefilled syringes labeled for use in adults Recent recommendations from the Advisory Committee on Immunization Practices (ACIP), published in December 2011, now emphasize the vaccination of adult patients with Diabetes Mellitus with Hepatitis B vaccines. In anticipation of increased use of Hepatitis B vaccines in this population, it is important to remind Health Care professionals that the age-appropriate formulation should be used. Recommendations: Use the different formulations of Engerix-B only in the age-appropriate groups (i.e., formulation labeled for pediatrics/adolescents should be used in persons aged <20 years, formulation labeled for adults should be used in persons aged 20 years and older). The adult Engerix-B is not approved for infants and children. Use of the adult Engerix-B in the year old age group is discouraged due to the expense of the vaccine, but if it is used it should count as a valid dose. Using the inappropriate formulation in an unlabeled age group may lead to medication errors including insufficient protection, or a higher risk of adverse effects. Please review the table below for dose and administration schedules for Engerix-B vaccines. In alignment with ACIP general immunization practice recommendations, any variation from the recommended route, site, volume, or number of doses of any vaccine is discouraged. In situations where there are shortages or unavailability of age-appropriate vaccines, alternative methods for immunization may be recommended. Engerix-B Dosing Table Age Dose (mcg) Volume (ml) Recommended Schedule Alternate Schedule Infants <1 yr , 1-2, and 6 months* 0, 1, 2, and 12 months Children 1-10 yrs , 1, and 6 months Adolescents 0, 1, 2, and 12 months -OR- 0, 12, and 24 months yrs , 1, and 6 months 0, 12, and 24 months Adults 20 yrs , 1, and 6 months 0, 1, 2, and 12 mos Hemodialysis and Immunocompromised Patients <20 yrs , 1, 2 and 6 months - 20 yrs , 1, 2 and 6 months - Booster Vaccinations 10 yrs When indicated Not applicable 11 yrs 20 1 When indicated Not applicable * Four doses total of Hepatitis B vaccine is permissible when a combination vaccine containing Hepatitis B antigen (e.g., Pediarix) is used after the birth dose A four-dose schedule may be used in infants born of HBsAg-positive mothers for prolonged maintenance of protective titers; these infants should also receive hepatitis B immune globulin (HBIG) An alternative extended administration schedule may be considered for children aged 5-10 years and adolescents; assess the risk for hepatitis B exposure Use of the adult Engerix-B formulation in this age group is not preferred; however, if administered then it will count as a valid dose Higher doses may be more immunogenic but no specific recommendations have been made May be administered as two 1-mL doses of adult Engerix-B administered at one site. A dialysis formulation of Recombivax HB (40 mcg/1 ml) is available. Medications Reviewed, but Not Added to the Denosumab (Prolia) 60 mg/ml injection, decision pending for the National MPD Tocilizumab (Actemra) single use vials, decision pending for the National MPD Ivacaftor (Kalydeco) 150 mg tablets, not added to the Commercial, decision pending for the National MPD Ezogabine (Potiga) tablets, decision pending for the National MPD Page 5
Formulary Additions, Cont.
u Formulary Additions... 1 u No Initial Fill 2 u standing Orders....... 2 u criteria Restricted........... 2 u Quantity Limits......... 3 u Medicare Formulary... 3 u drug Benefit Update: 2012 Medicare
More informationFormulary. Update. At A Glance. Formulary Additions ISSUE 4 VOLUME 11 AUGUST 2017
ISSUE 4 VOLUME 11 AUGUST 2017 u Formulary Additions....... 1 unew Criteria Restricted Medications................2,3 umedications not added to the Formulary............ 3 unational Medicare Part D Formulary..................4
More informationISSUE 3 VOLUME 10 JUNE
u Formulary Additions..... 1 unew Criteria Restricted Medications............. 2 u Quantity Limits......... 2 u Floorstock Lists........ 3 u Medications Reviewed at P&T, But Not Added to the Formulary..............
More informationPrior Authorization Required: Yes as shown below
PROLIA, XGEVA (denosumab) MB9409 Covered Service: Prior Authorization Required: Additional Information Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes as shown below Must be
More informationFormulary. Update. Kaiser Permanente Georgia 1
u Formulary Additions..... 1 ISSUE 3 VOLUME 7 JUNE 2013 u Formulary Deletions......1 u Quantity Limits......... 2 u New Criteria Restricted Medications............. 2 u Floorstock Additions.... 2 u National
More informationAgenda. Richard Moriarty, MD, FAAP, Co-Director, MCAAP Immunization Initiative. Pentacel Vaccine Shortage Update MMRV Vaccine (Proquad ) Update
Massachusetts Department of Public Health Division of Epidemiology and Immunization Agenda Introduction Richard Moriarty, MD, FAAP, Co-Director, MCAAP Immunization Initiative Pentacel Vaccine Shortage
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationWhat s New With Immunizations
What s New With Immunizations 2018 Annual Update COURTNEY A. ROBERTSON, PHARMD, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF LOUISIANA AT MONROE COLLEGE OF PHARMACY Disclosures No financial disclosures
More informationVaccination Decision Making: What Providers Need to Know
Objectives Vaccination Decision Making: What Providers Need to Know Kelli Smith, RN, BSN Iowa Department of Public Health Immunization Program Catch-up Schedule: how to most efficiently bring persons up-to-date
More informationVaccine Label Examples
Vaccine Label Examples With the large amount of vaccine carried in most clinics, staff can easily become confused about vaccines within the storage unit. Labeling the area where vaccines are stored can
More information9/12/2018. Hepatitis B Virus Infection. Hepatitis B Infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Hepatitis B and Hepatitis B Vaccine Adult Track Chapter 10 Photographs and images included in this presentation
More informationImmunizations: An Overview. Sutter Health May 9, 2017 John Apostolo, PharmD, MBA Heidi Rens, PharmD
Immunizations: An Overview Sutter Health May 9, 2017 John Apostolo, PharmD, MBA Heidi Rens, PharmD Sutter Health: System Overview 2 Agenda Sutter Health Overview Sutter Health Vaccine overview Clinical
More informationCoventry Health Care of Georgia, Inc.
Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan
More informationAnnual Influenza Review
Annual Influenza Review 2017-2018 A review of past flu trends and what to expect in the coming season. Count on Our Support, Educational Resources and Products to Help You Prepare for the Next Influenza
More informationImmunization Update Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist
Immunization Update 2018 Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist Disclosures Merck speakers bureau Vaxserve speakers bureau Mrs. Jones shows up for her second ShingRix
More informationVaccine Label Examples
Vaccine Label Examples With the large amount of vaccine carried in most clinics, staff can easily become confused about vaccines within the storage unit. Labeling the area where vaccines are stored can
More informationNEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE Thomas R. Frieden, MD, MPH Commissioner
NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE Thomas R. Frieden, MD, MPH Commissioner Interim Guidance on Dosage, Precautions, and Adverse Effects of Antiviral Medications used to Treat or Prevent
More informationFormulary. Update. At A Glance. Formulary Additions
ISSUE 2 VOLUME 8 APRIL 2014 u Formulary Additions..... 1 u Formulary Deletions......2 u New standing Order...... 2 u Floorstock Additions.... 3 u Quanitity Limits........ 3 u New Approved Compound.. 3
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationFrom: New York State Department of Health, Bureau of Communicable Disease Control, Immunization Program
November 3, 2008 To: Hospitals, Providers, Local Health Departments From: New York State Department of Health, Bureau of Communicable Disease Control, Immunization Program HEALTH ADVISORY: USE OF PENTACEL
More informationJune 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationImmunization Update 2018
Immunization Update 2018 Keri Hurley-Kim, PharmD, MPH Assistant Professor, Department of Pharmacy Practice West Coast University School of Pharmacy Conflicts of Interest Keri Hurley-Kim declares no conflicts
More informationNUTS AND BOLTS OF A PHARMACY-BASED IMMUNIZATION CLINIC. Amy Bachyrycz, Pharm.D.
NUTS AND BOLTS OF A PHARMACY-BASED IMMUNIZATION CLINIC Amy Bachyrycz, Pharm.D. Policy and Procedures Manual Licensure/certifications Pharmacy license Pharmacists license CPR certification for each pharmacist
More informationTools for Targeting High Risk Patients in Your Practice. Statement of Disclosure
Tools for Targeting High Risk Patients in Your Practice Joseph Vande Griend, PharmD, BCPS, CGP Assistant Professor, University of Colorado Departments of Clinical Pharmacy and Family Medicine Skaggs School
More informationPOSITION STATEMENT. Safer design of vaccines packaging and labelling
2015 POSITION STATEMENT Safer design of vaccines packaging and labelling POSITION STATEMENT The International Medication Safety Network recommends the following steps as part of a comprehensive, worldwide
More informationInfluenza Immunization Drug Cards. New Brunswick (2017/18)
Influenza Immunization Drug Cards New Brunswick (2017/18) Contents Identifying Duplicate Drug Records... 1 Fluzone Quadrivalent - Pack Size 0.5... 3 Main Drug Card... 9 General Tab... 10 Plans Tab... 10
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE August 30, 2010 EFFECTIVE DATE August 30, 2010 MEDICAL ASSISTANCE BULLETIN NUMBER 01-10-27, 08-10-28, 09-10-29, 31-10-30, 33-10-05 SUBJECT: Updates to the Medical Assistance Program Fee Schedule
More information2018 Adult Immunization Schedule
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases 2018 Adult Immunization Schedule National Adult Immunization Coordinators Partnership Quarterly Meeting
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationIssues for Part D Compliance
HCCA- MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE Issues for Part D Compliance Craig Miner, RPh, JD Division of Drug Plan Policy Babette S. Edgar, Pharm.D., MBA Division of Finance and Operations
More informationLana Hudanick RN, BSN Public Health Consultant Nurse Bureau of Immunization Assessment and Assurance Missouri Department of Health and Senior
Lana Hudanick RN, BSN Public Health Consultant Nurse Bureau of Immunization Assessment and Assurance Missouri Department of Health and Senior Services Identify the appropriate vaccines and the Advisory
More informationPharmacy Audit Recovery Guidelines
1/1E DAW 1 DAW 1 Error The prescription order does not indicate the prescriber ordered brand name. 2 /2E DAW 2 DAW 2 Not Documented The documentation does not specify the patient s request for brand. Pharmacy
More informationGetting started with Prime
Getting started with Prime How does a pharmacy plan work? When you visit your doctor, he or she may prescribe medicine for you. Here's how the plan works: Take your prescription and member ID card to the
More informationPharmacy benefit guide
FlexRx SM 5-Tier Pharmacy benefit guide 1 Welcome to FlexRx The NHP FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many common medications
More informationTamiflu. Tamiflu (oseltamivir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.19 Subject: Tamiflu Page: 1 of 5 Last Review Date: March 18, 2016 Tamiflu Description Tamiflu (oseltamivir)
More informationFlexRx 6-Tier. SM Pharmacy Benefit Guide
FlexRx 6-Tier SM Pharmacy Benefit Guide Welcome to FlexRx The AllWays Health Partners FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationMedication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016
Medication Safety Patient Safety Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016 1 The patient journey Admission Ward Transfer Ward stay Discharge Medication storage and supply
More informationThe Use of Combination Vaccines in the United States
The Use of Combination Vaccines in the United States John W Ward, MD Senior Scientist, CDC Director, Program for Viral Hepatitis Elimination Task Force for Global Health Revised 2018 Combination Vaccine
More informationCase Study Activity: Strategies to Support the Safe Use of Acetaminophen
Case Study Activity: Strategies to Support the Safe Use of Acetaminophen Case 3: Preventing Therapeutic Duplication With Over-the-Counter Acetaminophen Products Activity Preview Acetaminophen is one of
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationInfluenza Immunization Drug Cards. Nova Scotia (2017/18)
Influenza Immunization Drug Cards Nova Scotia (2017/18) Contents Identifying Duplicate Drug Records... 1 FluLaval Tetra Influenza Vaccine - Pack Size 5... 4 Main Drug Card... 4 General Tab... 5 Plans Tab...
More informationAPIDRA (insulin glulisine) injection vial APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector
APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationInfluenza Clinical Bulletin # 3: October 8, 2009 Vaccination Guidelines for Patients for Influenza
The purpose of this document is to provide NYP providers with the most current recommendations regarding influenza vaccination for their patients. It is important to recognize that guidance reflects optimal
More informationSEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS
2015-2016 SEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS Office of the Chief Medical Officer of Health Communicable Disease Control Branch Immunization Program August 2015 Table of Contents
More informationInfluenza Immunization Drug Cards. Alberta 2018/19
Influenza Immunization Drug Cards Alberta 2018/19 Table of Contents Influenza Immunization Drug Cards Alberta (2018/19)...2 Identifying Duplicate Drug Records...2 Fluzone Quadrivalent Pack Size 5...5 Main
More informationTechnician Tutorial: The Basics of Immunization and Vaccines
(Page 1 of 5) Technician Tutorial: The Basics of Immunization and Vaccines Vaccines are considered one of the most important contributions to public health ever. Since the introduction of vaccines many
More informationImmunization Guidelines for the Use of State Supplied Vaccine May 17, 2015
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationH1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009
August 6, 2009 H1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009 CDC s Advisory Committee on Immunization Practices (ACIP), a panel made up of medical and public health experts, met July 29, 2009,
More informationISMP National Medication Error Reporting Program and Vaccine Error Reporting Program Operated by the Institute for Safe Medication Practices
ISMP National Medication Error Reporting Program and Vaccine Error Reporting Program Operated by the Institute for Safe Medication Practices www.ismp.org ISMP is a federally certified patient safety organization
More informationInfluenza Immunization Drug Cards. Ontario 2018/19
Influenza Immunization Drug Cards Ontario 2018/19 Table of Contents Influenza Immunization Drug Cards Ontario (2018/19)...2 Identifying Duplicate Drug Records...2 Fluzone Quadrivalent - Pack Size 5...5
More informationDisclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations
49th Annual Meeting Non-Sterile Compounding/ Sunil Jambhekar, B. Pharm., M.S., Ph.D Professor, Pharmaceutical Sciences LECOM Bradenton, School of Pharmacy Bradenton, FL 34211 Disclosure I do not have a
More informationPreventive care guidelines for children and adults.
Preventive care guidelines for children and adults. Keeping a focus on regular preventive care can help you and your family stay healthy. Preventive care can help you avoid potentially serious health conditions
More informationIMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe
IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe Read all of this leaflet carefully before you are vaccinated or before you have your child vaccinated. Keep
More informationPlanning for the Novel H1N1 Influenza Vaccination Campaign
Planning for the Novel H1N1 Influenza Vaccination Campaign Debra Blog, MD, MPH, Director Bureau of Immunization New York State Department of Health October 7, 2009 1 Influenza Prevention Influenza vaccination
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationVACCINE MANAGEMENT. Recommendations for Handling and Storage of Selected Biologicals. January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES
VACCINE MANAGEMENT Recommendations for Handling and Storage of Selected Biologicals January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES DTaP: Diphtheria Toxoid, Tetanus Toxoid, Acellular Pertussis Vaccine
More informationTable of Contents. 1.0 INFANRIX hexa VACCINE...3
Table of Contents 1.0 INFANRIX hexa VACCINE...3 1.1 What is INFANRIX hexa vaccine?...3 1.2 When will INFANRIX hexa be introduced?...3 1.3 What is the difference between INFANRIX hexa and Pediacel?...3
More informationPREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.
An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 55 March 2012
Area Drug and Therapeutics Committee Prescribing Supplement No 55 In this issue Drugs reviewed by the SMC in February 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationFLUOXETINE 60 MG oral tablet FLUOXETINE 90 MG oral delayed release (once weekly) capsule
FLUOXETINE 90 MG oral delayed release (once weekly) capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationAdult Immunization Update 2015
Adult Immunization Update 2015 Objectives Upon completion of this session, the pharmacist should be able to: Compare and contrast previous versions of the ACIP immunization schedules with the most recent
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:
More informationInfluenza Immunization Drug Cards. Ontario (2017/18)
Influenza Immunization Drug Cards Ontario (2017/18) Contents Identifying Duplicate Drug Records... 1 Fluzone Quadrivalent - Pack Size 5... 3 Main Drug Card... 3 General Tab... 4 Plans Tab... 4 Fluzone
More information09/17/2018. Standing Order for Influenza Vaccine for SKIIP Participants
Purpose: To reduce the morbidity and mortality of influenza by vaccinating those children and adolescents who meet the criteria established by the Centers for Disease Control and Prevention s (CDC) Advisory
More informationDrug Class Literature Scan: Pancreatic Enzymes
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPROLIA: Medical Coverage Policy Denosumab (Prolia and. Xgeva) EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Denosumab (Prolia and Xgeva) EFFECTIVE DATE: 11 01 2016 POLICY LAST UPDATED: 12 19 2017 OVERVIEW Prolia (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis
More informationUpdate: Erythropoiesis-Stimulating Agents
Mandy C. Leonard, Pharm.D., BCPS Assistant Director, Drug Information Service Meghan K. Lehmann, Pharm.D., BCPS Drug Information Specialist Dana L. Travis, R.Ph. David A. White, B.S., R.Ph. Restricted
More informationVaccinations Outside Recommended Ages 2014; Six Immunization Information System Sentinel Sites
National Center for Immunization & Respiratory Diseases Vaccinations Outside Recommended Ages 2014; Six Immunization Information System Sentinel Sites Loren Rodgers, Ph.D. CDC Immunization Information
More informationFlu Vaccine Access Via Pharmacy Vaccine Network
Re: Flu Vaccine Access Via Pharmacy Vaccine Network Effective 9/15/2016, IEHP Medi-Cal and Medicare DualChoice Cal MediConnect (IEHP Direct) Members who are over 18 years old may obtain Flu Vaccines through
More informationInfluenza Immunization Drug Cards. Saskatchewan 2018/19
Influenza Immunization Drug Cards Saskatchewan 2018/19 Table of Contents Influenza Immunization Drug Cards Saskatchewan (2018/19)...2 Identifying Duplicate Drug Records...2 FluLaval Tetra Influenza Vaccine
More informationStart your patient s drug education
PDR Network Provider Solutions: PDR + for Patients Here Start your patient s drug education So They Get Here FREE Patient Drug Education from PDR PDR+ helps you educate your patients about their prescriptions.
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationImmunization Guidelines For the Use of State Supplied Vaccine July 1, 2011
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationQuality measures a for measurement year 2016
Quality measures a for measurement year 2016 Measure Description Eligible members Childhood immunizations b Adolescent immunizations b Children who turned 2 during the measurement and who were identified
More informationKenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association
Kenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize
More informationHow to create a successful vaccine program
How to create a successful vaccine program Nothing to disclose and no conflicts of interest Vaccine Overview Vaccine Guidelines Purchasing: Supply, Manufacturers, Storage, Returns Reimbursement Codes
More informationMODEL INSERT MEASLES, MUMPS AND RUBELLA (MMR) COMBINED VACCINE
MODEL INSERT MEASLES, MUMPS AND RUBELLA (MMR) COMBINED VACCINE DESCRIPTION The vaccine is a freeze-dried powder containing three viruses - measles, mumps and rubella. a) The measles vaccine component is
More informationAspirin. Iron Supplements
Interim Final Rules for Non-Grandfathered Group Health Plans and Health Insurance Issuers Coverage of Preventive Services Under the Patient Protection and Affordable Care Act Aspirin Aspirin to Prevent
More informationPentabio Vaccine (DTP-HB-Hib)
SUMMARY OF PRODUCT CHARACTERISTICS Product Name Pharmaceutical Form Strength Presentation : Pentabio : Suspension for injection : 1, 5 and 10 doses : Box of 10 vials @ 0.5 ml Box of 10 vials @ 2.5 ml Box
More informationSupporting our provider partners through communication and collaboration. Formulary Updates
Supporting our provider partners through communication and collaboration. DATE DECEMBER 2014 ISSUE 4 HELPFUL NUMBERS FOR PROVIDERS Passport Health Plan Magellan: 1-800-846-7971 Bin: 016523 Processor control:
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
Ezetimibe-simvastatin 10-80 mg oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)
PATIENT / USER INFORMATION LEAFLET Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human) Read all of this leaflet carefully before you start taking this medicine. Keep this
More informationPREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.
An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation
More informationChapter 11 How to state your conditions clearly to the doctor
Chapter 11 How to state your conditions clearly to the doctor Chapter 11 How to state your conditions clearly to the doctor While seeing doctor, details of your statement should include the following:
More informationTreatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie )
Treatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO
More informationLEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector
LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationRAYOS (prednisone tablet delayed release) oral tablet
RAYOS (prednisone tablet delayed release) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationAllergy Status Identification And Documentation
Allergy Status Identification And Documentation Basic Medication Safety (BMS) Certification Course King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs Learning
More informationFrequently Asked Questions
Page 1 Frequently Asked Questions Codeine and all multiple-ingredient products containing codeine are restricted on the AHS Provincial Drug Formulary to patients 18 years of age and older. 1. What does
More informationVaricella (Chickenpox) and Varicella Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Varicella (Chickenpox) and Varicella Vaccines September 2018 Photographs and images included in this
More informationPrescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks
Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks Patient Health and Safety Guidelines Prescription Medications Policy Update / April 2017 In connection
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
Metformin tablet SR 24-hour modified release oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationImmunization Update 2017 Peds Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2017 Peds Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Hepatitis B Meningococcal
More information